Surrozen Doses First Patient in Alcohol-Associated Hepatitis Study

Surrozen, Inc. (Nasdaq: SRZN), has dosed the first patient in a Phase 1b clinical study of SZN-043 in patients with severe alcohol-associated hepatitis. The open-label, multi-center clinical trial will enroll approximately 30 patients and will evaluate SZN-043, the company’s first development candidate using Surrozen’s SWEETS™ technology.

Commenting on the news, Craig Parker, President and Chief Executive Officer of Surrozen, said, “We are gaining momentum in our SZN-043 clinical trial program in severe alcohol-associated hepatitis and anticipate that proof-of-concept data may be available in the first half of 2025.”

Surrozen successfully completed a Phase 1a clinical trial in patients with chronic liver disease and healthy volunteers. In the study, SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement.

Edward Gane MBCHB, MD, FRACP, MNZM, Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at the Auckland City Hospital, commented, “Severe alcohol-associated hepatitis remains an unmet medical need with a very high mortality and no improvement in survival for more than 50 years. I am very excited about the potential for SZN-043 to offer a meaningful clinical benefit to these patients.”

About Surrozen

Surrozen is a clinical stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. For more information, please visit

Share This Article


About the Author

Surrozen Doses First Patient in Alcohol-Associated Hepatitis Study

Catie Corcoran

Biotech Editor